DGIdb - BRCA2 Gene Record

BRCA2 675 Clinically Actionable

Alternate Names:

675
BRCA2, DNA REPAIR ASSOCIATED
BRCA2
BRCC2
BROVCA2
FACD
FAD
FAD1
FANCD
FANCD1
GLM3
PNCA2
XRCC11
600185
1101
ENSG00000139618
OTTHUMG00000017411
7
PA25412

Gene Info:

Gene Biotype	PROTEIN_CODING

(8 More Sources)

Gene Categories: Category Details

CLINICALLY ACTIONABLE

Publications:

de Bono et al., 2017, Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers., Cancer Discov
Mo et al., 2016, mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer., Clin. Cancer Res.
Shen et al., 2013, BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency., Clin. Cancer Res.
Hunter et al., 2014, Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer., Mol. Cancer Ther.
Rodler et al., 2016, Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer., Clin. Cancer Res.
O'Reilly EM et al., 2018, Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma., Cancer
Isakoff et al., 2015, TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer., J. Clin. Oncol.
Xu et al., 2017, CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours., Nat Commun
Liu et al., 2014, Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study., Lancet Oncol.
Mirza et al., 2016, Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer., N. Engl. J. Med.
Du et al., 2016, Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors., Nat. Med.
Drew et al., 2016, Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer., Br. J. Cancer
Shroff RT et al., 2018, Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious <i>BRCA</i> Mutation., JCO Precis Oncol
Swisher et al., 2017, Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial., Lancet Oncol.
Stachelek et al., 2015, YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors., Mol. Cancer Res.
Valiakhmetova A et al., 2020, Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response., Oncologist
2017 Aug 9, Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation., N Engl J Med
Gelmon et al., 2011, Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study., Lancet Oncol.
Fong et al., 2009, Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers., N. Engl. J. Med.
Kaufman et al., 2015, Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation., J. Clin. Oncol.
Robson et al., 2017, Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation., N. Engl. J. Med.
Mateo et al., 2015, DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer., N. Engl. J. Med.
Goff, 2013, Advanced ovarian cancer: what should be the standard of care?, J Gynecol Oncol
Tutt et al., 2010, Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial., Lancet
Kortmann et al., 2011, Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts., Clin. Cancer Res.
Shah et al., 1975, Cardiovascular effects of beta-receptor stimulants in healthy volunteers., Indian Heart J
Akamatsu et al., 1975, Increase in acetyl CoA synthetase activity after phenobarbital treatment., Biochem. Pharmacol.
Tan et al., 1975, Characteristics of the dephosphorylated form of phosphorylase purified from rat liver and measurement of its activity in crude liver preparations., Biochim. Biophys. Acta
1991, Thallium scintigraphy., Lancet
Golan T et al., 2019, Maintenance Olaparib for Germline <i>BRCA</i>-Mutated Metastatic Pancreatic Cancer., N Engl J Med
Moore K et al., 2018, Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer., N Engl J Med
Ledermann J et al., 2014, Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial., Lancet Oncol
de Bono J et al., 2020, Olaparib for Metastatic Castration-Resistant Prostate Cancer., N Engl J Med
Marshall CH et al., 2019, Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations., Eur Urol
Kummar et al., 2015, Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer., Clin. Cancer Res.
Fogelman DR et al., 2011, Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer., Anticancer Res
McGonigle et al., 2015, E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling., Oncotarget
LoRusso et al., 2016, Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors., Clin. Cancer Res.
Dillon et al., 2017, Radiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei., Mol. Cancer Ther.

EVOFOSFAMIDE BRCA2

Interaction Score: 4.54

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal adenocarcinoma

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
25193512

Sources:
JAX-CKB
INIPARIB BRCA2

Interaction Score: 2.27

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21508395

Sources:
CIViC
PR-104 BRCA2

Interaction Score: 2.27

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal adenocarcinoma

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
25193512

Sources:
JAX-CKB
OLAPARIB BRCA2

Interaction Score: 2.12

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type ovarian cancer

Response Type sensitive

Approval Status Preclinical - Pdx

PMIDs:
32043779 28792849 21862407 25218906 19553641 25366685 28578601 26510020 23346317 26546619 26116172 20609467 21097693 322 15 75 1682772 31157963 30345884 24882434 32343890 30797618

Sources:
ClearityFoundationBiomarkers JAX-CKB CGI CIViC PharmGKB OncoKB
VELIPARIB BRCA2

Interaction Score: 1.82

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type prostate cancer

Response Type sensitive

Approval Status Phase II

PMIDs:
29338080 25589624 26842236 26801247

Sources:
ClearityFoundationBiomarkers JAX-CKB CGI CIViC
QUARFLOXIN BRCA2

Interaction Score: 1.51

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28211448

Sources:
CIViC
TALAZOPARIB BRCA2

Interaction Score: 1.45

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type triple-receptor negative breast cancer

Response Type decreased response

Approval Status Phase I

PMIDs:
28242752 26546619 23881923

Sources:
JAX-CKB CIViC PharmGKB OncoKB
NIRAPARIB BRCA2

Interaction Score: 1.26

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type predicted – sensitive

Evidence Type Actionable

Approval Status Phase III

PMIDs:
27717299

Sources:
ClearityFoundationBiomarkers JAX-CKB PharmGKB OncoKB
CERALASERTIB BRCA2

Interaction Score: 1.14

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AZD6738 + Radiotherapy

Indication/Tumor Type colorectal adenocarcinoma

Response Type sensitive

PMIDs:
28062704

Sources:
JAX-CKB
2X-121 BRCA2

Interaction Score: 1.14

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Preclinical

PMIDs:
26513298

Sources:
ClearityFoundationBiomarkers JAX-CKB
PAMIPARIB BRCA2

Interaction Score: 0.76

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type ovarian cancer

Response Type predicted – sensitive

Approval Status Phase I

PMIDs:
None found

Sources:
JAX-CKB
RUCAPARIB BRCA2

Interaction Score: 0.69

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family PARP inhibitor

Alteration BRCA2:.

Indication/Tumor Type ovarian cancer

PMIDs:
26779812 27002934 30051098 27908594

Sources:
ClearityFoundationBiomarkers JAX-CKB CGI CIViC PharmGKB OncoKB
CHLORAMBUCIL BRCA2

Interaction Score: 0.38

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal adenocarcinoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
25193512

Sources:
JAX-CKB
BERZOSERTIB BRCA2

Interaction Score: 0.25

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Cisplatin + VX-970

Indication/Tumor Type triple-receptor negative breast cancer

Response Type predicted – sensitive

PMIDs:
None found

Sources:
JAX-CKB
TEMOZOLOMIDE BRCA2

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
32043779

Sources:
CIViC
VINORELBINE BRCA2

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Cisplatin + Veliparib + Vinorelbine

Indication/Tumor Type Her2-receptor negative breast cancer

Response Type predicted – sensitive

PMIDs:
26801247

Sources:
JAX-CKB
EVEROLIMUS BRCA2

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Everolimus + Talazoparib

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

PMIDs:
26546619

Sources:
JAX-CKB
CISPLATIN BRCA2

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

Alteration BRCA2:.

Drug family PARP inhibitor;Chemotherapy

combination therapy Veliparib;Cisplatin

PMIDs:
25193512 26801247 29338080 25847936

Sources:
JAX-CKB CGI CIViC
CEDIRANIB BRCA2

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25218906

Sources:
CIViC
ETOPOSIDE BRCA2

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type sensitive

PMIDs:
26116172

Sources:
JAX-CKB
CARBOPLATIN BRCA2

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Veliparib + Carboplatin

Indication/Tumor Type breast cancer

Response Type predicted – sensitive

PMIDs:
25847936

Sources:
JAX-CKB CIViC
IRINOTECAN BRCA2

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Irinotecan + Veliparib

Indication/Tumor Type ovarian cancer

Response Type predicted – sensitive

PMIDs:
26842236

Sources:
JAX-CKB
CYCLOPHOSPHAMIDE BRCA2

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Veliparib + Cyclophosphamide

Indication/Tumor Type ovarian cancer

Response Type no benefit

PMIDs:
25589624

Sources:
JAX-CKB
GEMCITABINE BRCA2

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29338080

Sources:
CIViC
PACLITAXEL BRCA2

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Carboplatin + Paclitaxel + Veliparib

Indication/Tumor Type breast cancer

Response Type predicted – sensitive

PMIDs:
None found

Sources:
JAX-CKB

Ensembl: ENSG00000139618
- Version: 101_38
Alternate Names:

BRCA2 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:

JAX-CKB: BRCA2

Version: 27-September-2017

Alternate Names:

675 CKB Entrez Id

BRCA2 CKB Gene Synonym

BRCC2 CKB Gene Synonym

Gene Info:

Publications:

Stachelek et al., 2015, YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors., Mol. Cancer Res.

Hunter et al., 2014, Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer., Mol. Cancer Ther.

McGonigle et al., 2015, E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling., Oncotarget

CIViC: BRCA2

Version: 14-September-2020

Alternate Names:

675 Entrez Gene ID

7 CIViC Gene ID

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:

Xu et al., 2017, CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours., Nat Commun

de Bono et al., 2017, Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers., Cancer Discov

Pennington et al., 2014, Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas., Clin. Cancer Res.

CGI: BRCA2

Version: 27-September-2017

Alternate Names:

Gene Info:

Publications:

Dann et al., 2012, BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer., Gynecol. Oncol.

Alsop et al., 2012, BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group., J. Clin. Oncol.

Mateo et al., 2015, DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer., N. Engl. J. Med.

OncoKB: BRCA2
- Version: 23-July-2020
Alternate Names:

675 OncoKB Entrez Id

FANCD1 OncoKB Gene Synonym

BROVCA2 OncoKB Gene Synonym

Gene Info:

Publications:
PharmGKB: BRCA2
- Version: 18-August-2020
Alternate Names:

PA25412 PharmGKB ID

Gene Info:

Publications:
Tempus: BRCA2
- Version: 11-November-2018
Alternate Names:

BRCA2 Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
ClearityFoundationBiomarkers: BRCA2
- Version: 26-July-2013
Alternate Names:

Gene Info:

Publications:
MskImpact: BRCA2
- Version: May-2015
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
FoundationOneGenes: BRCA2
- Version: 03-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
CarisMolecularIntelligence: BRCA2
- Version: 04-September-2020
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
Oncomine: BRCA2
- Version: v3
Alternate Names:

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:

Indication/Tumor Type	colorectal adenocarcinoma
Response Type	sensitive
Approval Status	Preclinical - Cell line xenograft

Indication/Tumor Type	ovarian cancer
Response Type	sensitive
Approval Status	Preclinical - Pdx

Indication/Tumor Type	prostate cancer
Response Type	sensitive
Approval Status	Phase II

Indication/Tumor Type	triple-receptor negative breast cancer
Response Type	decreased response
Approval Status	Phase I

Response Type	predicted – sensitive
Evidence Type	Actionable
Approval Status	Phase III

combination therapy	AZD6738 + Radiotherapy
Indication/Tumor Type	colorectal adenocarcinoma
Response Type	sensitive

Indication/Tumor Type	Advanced Solid Tumor
Response Type	sensitive
Approval Status	Preclinical

Drug family	PARP inhibitor
Alteration	BRCA2:.
Indication/Tumor Type	ovarian cancer

combination therapy	Cisplatin + VX-970
Indication/Tumor Type	triple-receptor negative breast cancer
Response Type	predicted – sensitive

combination therapy	Cisplatin + Veliparib + Vinorelbine
Indication/Tumor Type	Her2-receptor negative breast cancer
Response Type	predicted – sensitive

combination therapy	Everolimus + Talazoparib
Indication/Tumor Type	triple-receptor negative breast cancer
Response Type	sensitive

combination therapy	Veliparib + Carboplatin
Indication/Tumor Type	breast cancer
Response Type	predicted – sensitive

combination therapy	Irinotecan + Veliparib
Indication/Tumor Type	ovarian cancer
Response Type	predicted – sensitive

combination therapy	Veliparib + Cyclophosphamide
Indication/Tumor Type	ovarian cancer
Response Type	no benefit

combination therapy	Carboplatin + Paclitaxel + Veliparib
Indication/Tumor Type	breast cancer
Response Type	predicted – sensitive

675	OncoKB Entrez Id
FANCD1	OncoKB Gene Synonym
BROVCA2	OncoKB Gene Synonym

BRCA2 Gene Record

BRCA2 675 Clinically Actionable

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type colorectal adenocarcinoma Response Type sensitive Approval Status Preclinical - Cell line xenograft

PMIDs: 25193512

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21508395

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type colorectal adenocarcinoma Response Type sensitive Approval Status Preclinical - Cell line xenograft

PMIDs: 25193512

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type ovarian cancer Response Type sensitive Approval Status Preclinical - Pdx

PMIDs: 32043779 28792849 21862407 25218906 19553641 25366685 28578601 26510020 23346317 26546619 26116172 20609467 21097693 322 15 75 1682772 31157963 30345884 24882434 32343890 30797618

Sources: ClearityFoundationBiomarkers JAX-CKB CGI CIViC PharmGKB OncoKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type prostate cancer Response Type sensitive Approval Status Phase II

PMIDs: 29338080 25589624 26842236 26801247

Sources: ClearityFoundationBiomarkers JAX-CKB CGI CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 28211448

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type triple-receptor negative breast cancer Response Type decreased response Approval Status Phase I

PMIDs: 28242752 26546619 23881923

Sources: JAX-CKB CIViC PharmGKB OncoKB

Interaction Types & Directionality: n/a

Interaction Info: Response Type predicted – sensitive Evidence Type Actionable Approval Status Phase III

PMIDs: 27717299

Sources: ClearityFoundationBiomarkers JAX-CKB PharmGKB OncoKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy AZD6738 + Radiotherapy Indication/Tumor Type colorectal adenocarcinoma Response Type sensitive

PMIDs: 28062704

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type Advanced Solid Tumor Response Type sensitive Approval Status Preclinical

PMIDs: 26513298

Sources: ClearityFoundationBiomarkers JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type ovarian cancer Response Type predicted – sensitive Approval Status Phase I

PMIDs: None found

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Drug family PARP inhibitor Alteration BRCA2:. Indication/Tumor Type ovarian cancer

PMIDs: 26779812 27002934 30051098 27908594

Sources: ClearityFoundationBiomarkers JAX-CKB CGI CIViC PharmGKB OncoKB

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type colorectal adenocarcinoma Response Type sensitive Approval Status Preclinical

PMIDs: 25193512

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Cisplatin + VX-970 Indication/Tumor Type triple-receptor negative breast cancer Response Type predicted – sensitive

PMIDs: None found

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 32043779

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Cisplatin + Veliparib + Vinorelbine Indication/Tumor Type Her2-receptor negative breast cancer Response Type predicted – sensitive

PMIDs: 26801247

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Everolimus + Talazoparib Indication/Tumor Type triple-receptor negative breast cancer Response Type sensitive

PMIDs: 26546619

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Alteration BRCA2:. Drug family PARP inhibitor;Chemotherapy combination therapy Veliparib;Cisplatin

PMIDs: 25193512 26801247 29338080 25847936

Sources: JAX-CKB CGI CIViC

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal adenocarcinoma

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
25193512

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
21508395

Sources:
CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal adenocarcinoma

Response Type sensitive

Approval Status Preclinical - Cell line xenograft

PMIDs:
25193512

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type ovarian cancer

Response Type sensitive

Approval Status Preclinical - Pdx

PMIDs:
32043779 28792849 21862407 25218906 19553641 25366685 28578601 26510020 23346317 26546619 26116172 20609467 21097693 322 15 75 1682772 31157963 30345884 24882434 32343890 30797618

Sources:
ClearityFoundationBiomarkers JAX-CKB CGI CIViC PharmGKB OncoKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type prostate cancer

Response Type sensitive

Approval Status Phase II

PMIDs:
29338080 25589624 26842236 26801247

Sources:
ClearityFoundationBiomarkers JAX-CKB CGI CIViC

Interaction Types & Directionality:

n/a

PMIDs:
28211448

Sources:
CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type triple-receptor negative breast cancer

Response Type decreased response

Approval Status Phase I

PMIDs:
28242752 26546619 23881923

Sources:
JAX-CKB CIViC PharmGKB OncoKB

Interaction Types & Directionality:

n/a

Interaction Info:

Response Type predicted – sensitive

Evidence Type Actionable

Approval Status Phase III

PMIDs:
27717299

Sources:
ClearityFoundationBiomarkers JAX-CKB PharmGKB OncoKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy AZD6738 + Radiotherapy

Indication/Tumor Type colorectal adenocarcinoma

Response Type sensitive

PMIDs:
28062704

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type Advanced Solid Tumor

Response Type sensitive

Approval Status Preclinical

PMIDs:
26513298

Sources:
ClearityFoundationBiomarkers JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type ovarian cancer

Response Type predicted – sensitive

Approval Status Phase I

PMIDs:
None found

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family PARP inhibitor

Alteration BRCA2:.

Indication/Tumor Type ovarian cancer

PMIDs:
26779812 27002934 30051098 27908594

Sources:
ClearityFoundationBiomarkers JAX-CKB CGI CIViC PharmGKB OncoKB

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type colorectal adenocarcinoma

Response Type sensitive

Approval Status Preclinical

PMIDs:
25193512

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Cisplatin + VX-970

Indication/Tumor Type triple-receptor negative breast cancer

Response Type predicted – sensitive

PMIDs:
None found

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

PMIDs:
32043779

Sources:
CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Cisplatin + Veliparib + Vinorelbine

Indication/Tumor Type Her2-receptor negative breast cancer

Response Type predicted – sensitive

PMIDs:
26801247

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Everolimus + Talazoparib

Indication/Tumor Type triple-receptor negative breast cancer

Response Type sensitive

PMIDs:
26546619

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Alteration BRCA2:.

Drug family PARP inhibitor;Chemotherapy

combination therapy Veliparib;Cisplatin

PMIDs:
25193512 26801247 29338080 25847936

Sources:
JAX-CKB CGI CIViC

Interaction Types & Directionality:

n/a

PMIDs:
25218906

Sources:
CIViC

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type sensitive

PMIDs:
26116172

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Veliparib + Carboplatin

Indication/Tumor Type breast cancer

Response Type predicted – sensitive

PMIDs:
25847936

Sources:
JAX-CKB CIViC